Abbott tells us it has received U.S. FDA approval for the fourth generation of of its MitraClip™ heart valve repair device to treat … continue reading “U.S. Approval for Next-Generation MitraClip®”
Japanese study data underpins approval
Helping treat patients with debilitating chronic pain and provideingrelief from hard-to-treat neuropathic conditions
System offers freedom from finger sticking for diabetic community
Device automatically captures vital cardiac information and relays data to physicians via smartphone app, enabling remote monitoring of irregular hearth rhythms
Study “validates that treatment with MitraClip can provide meaningful reduction in the severity of mitral regurgitation”
Enhanced system allows better 3D images of anatomical sources of irregular heartbeat
Abbott is making its intentions clear with its transcatheter mitral valve acquisition
Japanese study presented at ESC2015 suggests absorbable stent performs as well as its metallic forebear
New generation of Abbott’s absorbable stent line features improved access and deliverability
It’s a simple concept. Hook the failing mitral valve leaflet and anchor it to the heart wall. Feasibility study suggests it might work too
MitraClip yields meaningful reduction in regurgitation, thereby offering an interventional alternative when surgery isn’t an option
Abbott has completed its acquisition of Topera, Inc., a company focused on technologies for the diagnosis and treatment of atrial fibrillation.
Abbott is to acquire Topera with its clever diagnostic catheter and mapping software that offers improved outcomes from cardiac ablation for atrial fibrillation.
Newly presented study findings provide reassurance that performance of Abbott’s fully absorbable coronary stent is equivalent to its metallic forebeer at one year.
Registry data suggests that use of MitraClip to reduce mitral valve regurgitation confers benefits in even severely ill patients.